CURRICULUM VITAE

http://www.linkedin.com/in/skongsamut

(August 2023)

Name: Sathapana (Sam) Kongsamut, Ph.D.

** ******* ***, *******, ** 07940

adz2ln@r.postjobfree.com; 973-***-**** (mobile)

Academic training: mini-MBA (Biopharma Innovation) 2015 Rutgers University

Postdoctoral training 1987 Cornell University & 1991 Yale University

Ph.D. (Neuropharmacology) 1986 University of Chicago

M.S. (Biology) 1982 University of Illinois

B.Sc. (Biology) 1979 University of Ottawa

GCE “O” and “A” levels British School, Netherlands

Highlights: Pharmacologist: Hematological oncology, Neuroscience.

Driving R&D efforts in cancer immunotherapy at BryoLogyx (a virtual company) through contracts and collaborations: preclinical experiments, translational science, clinical development, CMC.

Co-founder of two startup biotech companies. Accomplished pharmaceutical industry scientist with expertise in oncology/cancer biology, immunology, virology, aging, neuroscience. Prior involvement with teaching, mentoring and consulting with universities, foundations, startups/biotechs.

External innovation specialist in age-related disorders: in-licensing and external collaborative networks with academia and biotechnology. Scouting and evaluation roles through due diligence contributing to deal-making (>200 opportunities evaluated, leading to 4 deals over 3 years). Provided advice to potential partners on attractive data packages.

Former member of CNS Board at Sanofi & Aventis, managing neuroscience project portfolio. Neuroscientist with expertise in neuropsychiatric disease, translational science: taking discoveries in the lab into clinical studies and therapies for patients. Led multi-disciplinary teams responsible for selecting compounds entering development (>10 development candidates entering preclinical development; 3 to Phase III, 2 to market). Biochemical pharmacologist responsible for department of up to 30 scientists working on ion channels, G-protein coupled receptors, and enzymes.

Mentor to entrepreneurs, intrapreneurs and projects helping to uncover the business value of novel technical ideas.

Employment:

2016-present BryoLogyx, Inc., Danville, CA

Founder and Vice-President, Research & Development

2016-2019 Board Member

Cancer immunotherapy & HIV cure

Strategic planning and execution of company R&D plans to develop bryostatin-1 and analogs

CRADA with NCI, other collaborations established

BryoLogyx is currently seeking funding to continue its work

2016-present Institute for Life Sciences Entrepreneurship, Union, NJ

Entrepreneur Center

Advisory Council Member

Work with ILSE management on an annual Regional Academic Drug Discovery Symposium (3 events to date) and establishing a Center for Translational Neuroscience

2012-present BioInvenu Corp., East Hanover, NJ

Vice-President, Business Development

Link LightTM protein-protein interaction technology

Recipient of 4 Ph1 and 1 Ph2 SBIR grants; set up collaborations; aid in commercialization

2012-2023 Rudder Serendip LLC, Madison, NJ

President

Consulting in pharmaceutical R&D and business development

-- Clients include biotechnology companies, venture funds, universities & disease-focused foundations.

-- Activities to date include: partnering with pharma, portfolio review, honing pitch presentations, R&D plans – incl. IND preparation, proof of concept and minimum viable product, business model, partnering/ licensing; due diligence reports, company formation and execution, grant writing & review (consortium grants, SBIR), making connections/introductions.

-- Clients include companies in NY/NJ, MA, IL, CO, Belgium, Singapore. More details available upon request.

2012-2015 Biochron Therapeutics, Madison, NJ

interim CEO – circadian rhythm modulation startup biotech company

2014-2015 Neurotrope Bioscience, Newark, NJ

Executive Director, Pharmacology

Responsible for pharmacology studies for lead compound bryostatin-1 in Alzheimer’s disease and lysosomal storage disorders (Niemann Pick Disease Type C) and Fragile X syndrome.

2004-2012 sanofi-aventis (sanofi, since May 2011), Bridgewater, NJ

2010-2012 Director, External Innovation, Aging Therapeutic Strategy Unit

Scouting and evaluation of partnership and licensing opportunities for various disease indications related to Aging

2008-2010 Director, External Opportunities and Innovation for Central Nervous System (CNS) Discovery and Director, Molecular and Functional Neuropharmacology

-- Member of CNS Board responsible for CNS portfolio.

-- Led global CNS licensing & collaboration efforts, coordinating across groups and driving decisions on evaluations of licensing opportunities.

-- Led and coached department of 30+ staff members divided into 3 groups (Molecular Systems, Lead Discovery, and Lead Optimization/Systems Biochemistry).

2004-2008 Assoc. Director, Lead Discovery, Molecular and Functional Neuropharmacology, Central Nervous Systems Therapeutic Department

-- Led and coached department of 15 staff members working on medium throughput screening & selection of compounds for development in various CNS disease indications.

1999-2004 Aventis Pharmaceuticals Inc, Bridgewater, NJ.

2001-2004 Senior Manager, Department of Molecular and Cellular Pharmacology, Central Nervous System Disease Group

-- Member of CNS Leadership Team responsible for portfolio, personnel & budget management

2000-2001 Head, Biochemical Pharmacology, Central Nervous System Disease Group

1995-1999 Hoechst Marion Roussel Inc., Bridgewater, NJ

1995-1999 Group Leader, Biochemical Pharmacology Laboratory, Department of Neuroscience

-- Headed lab group responsible for screening of compounds in a variety of biochemical assays. Application of biochemical techniques to various drug discovery projects including projects related to the treatment of Schizophrenia, Depression, Anxiety, Sleep Disorders, obsessive compulsive disorder (OCD), Alzheimer’s Disease, Spinal Cord Injury, and Stroke

1991-1995 Hoechst Roussel Pharmaceuticals Inc., Somerville, NJ

1991-1995 Senior Research Biochemist, Neuroscience Strategic Business Unit

-- Led OCD research efforts, and ran compound screening lab, providing rapid results feedback

1987-1991 Yale University School of Medicine

New Haven, CT 06510

1989-1991 Postdoctoral associate

Department of Pharmacology

Worked on mechanism of the inhibitory effects of dopamine, GABA and peptides on alphaMSH secretion from melanotrophs of the pituitary neurointermediate lobe.

with Dr. William W. Douglas

19871989 Postdoctoral associate

Department of Cellular and Molecular Physiology

Worked on neurotransmitter release from frog sympathetic ganglion neurons and its regulation by modulators of voltage sensitive Ca channel activity.

with Dr. Richard W. Tsien

19861987 Cornell University Medical College

Department of Physiology

New York, NY 10021

Postdoctoral fellow

Worked on regulation of intracellular Ca concentration particularly by Na/Ca exchange in rat brain synaptosomes as it pertains to neurotransmitter release. Began to setup rapid mixing and rapid release apparatus to study Ca regulation and secretion in the millisecond time scale.

with Dr. Daniel A. Nachshen (Dr. Nachshen passed away Dec. 1986)

Education:

2015 Rutgers University

Rutgers Business School Executive Education

Piscataway, NJ

Mini-MBA (BioPharma Innovation)

1981 1986 University of Chicago

Department of Pharmacological and Physiological Sciences

Chicago, IL 60637

Ph.D. (Neuropharmacology) completed February 1986

Thesis: "Pharmacology of Voltage Sensitive Calcium Channels in Cultured Cells". Worked on calcium channel agonist and antagonist compounds and their interaction with calcium channels in a variety of muscle and neuronal cell lines. Examined a variety of toxins and other natural products with potential interactions with calcium channels.

with Dr. Richard J. Miller

1979 1981 University of Illinois at Chicago

Department of Biological Sciences

Chicago, IL 60680

M.S. (Biology) completed January 1982

Thesis: "Localization and Some Properties of Opiate Binding Sites in the Central Nervous System of the Frog Rana pipiens"

with Dr. Paul D. Pezalla

1975 1978 University of Ottawa

Ottawa, Ontario, Canada K1N 6N5

B.Sc. (Biology) received May 1979

Scientific & Educational Activities:

2023-present Steering Committee Member, FWO-SBO (Belgium/Flanders life sciences funding agency), Brussels, Belgium

2016-present RISE Associate Fellow, Drew Univ., Research Institute for Scientists Emeriti, Madison, NJ

1993-present Adjunct Faculty Member, Department of Pharmacology and Physiology, Rutgers University, New Jersey Medical School (formerly UMDNJ)

2012-present Scientific Review Board, Alzheimer’s Drug Discovery Foundation, New York, NY

2015-present Review Panel, Robertson Therapeutics Development Fund, Rockefeller University

2015-present Review Panel, NIH REACH (Research Evaluation And Commercialization Hub), Long Island BioScience Hub; Mentor to regional biotech/biopharma companies

2014-present Mentor, ELAB NYC (entrepreneurial training program)

2012-2016 Advisory Board, BioPharma Research Council, Tinton Falls, NJ

2014-2016 Co-organizer, Launch NJ Life Sciences Hub, entrepreneur group

2013-2014 External Member, Institutional Review Board, NJ Institute of Technology, Newark NJ

2016 Executive in Residence, CCIT-NJ Life Sciences Incubator, North Brunswick, NJ

2013 Executive-in-residence, Columbia University, Technology Ventures, New York, NY

2015-present Collaborating Partner, PharmaNest/MedNest, Princeton, NJ

Working languages: English, French, Thai; some knowledge of Dutch, German

Membership in Scientific Societies:

New York Academy of Sciences

Previous: American Association for the Advancement of Science

American Chemical Society

Gerontological Society of America (GSA)

Licensing Executives Society

Society for Neuroscience, International Brain Research Organization (IBRO)

Awards, Invitations and miscellaneous activities:

1980-present Ad-hoc reviewer, various journals

197981 University of Illinois Teaching Assistantship

198283 University of Chicago SUNNY Scholarship

198384 Smith Scholarship in Physiology

198486 University of Chicago Divisional unendowed funds

1986 Invited Speaker, McGill University, Montreal, Canada

1986 Invited Speaker, City University of New York, New York, USA

1988 (IBRO) Invited Speaker, First Intensive Workshop on Basic Neuroscience, Bangkok

1988 Invited Speaker, University of Ottawa, Ottawa, Canada

1989-91 National Research Service Award (NS-07136)

1991 Invited Speaker, University of British Columbia, Vancouver, Canada

1991 Invited Speaker, University of Florida, Gainesville, Florida, USA

1991 Invited Speaker, Chicago Medical School, North Chicago, Illinois, USA

1994 Organized and chaired meeting between University of North Carolina faculty and

Hoechst researchers to discuss projects of mutual interest

1994 Adjunct Professor, teaching in Membrane Transport course

1996 Adjunct Professor, teaching in Medical Physiology course

1996 Invited Speaker, Rutgers University

regularly Invited Speaker, Mahidol University, Bangkok, Thailand

1997 Invited Speaker, Center for Natural Products Research, National Univ. of Singapore

1993, 1996, 1997 Invited Speaker, Lecturer, University of Medicine and Dentistry of New Jersey

1998-2012 Neuroscience Teacher-Partner Program, Society for Neuroscience (visit schools to encourage students’ interest in science/neuroscience: 2-3 school visits per year)

1998-present Editorial Board, CNS Neuroscience & Therapeutics (formerly CNS Drug Reviews)

2000 Coorganizer, “Careers – It’s not all Academic” Symposium, UMDNJ

2001 Invited Scientist & Lecturer, Mahidol University, Bangkok, Thailand

Three-week series of lectures on the drug discovery and development process

2002 Invited Speaker, Columbia University, lectured on the drug discovery and development process

2002 Invited Speaker, NCDEU (Boca Raton, FL), 5HT2 Antagonists, What good are they?

2002-2003 M.Sc. Thesis Advisor to Joseph Tweed (Thomas Jefferson University, completed 2003);

2003 Invited Speaker, Strategic Research Institute conference on Psychiatric Drug Discovery and Development

2003 Invited Speaker, Dept. Pharmacology and Physiology, UMDNJ, Dopamine Receptors in the treatment of Schizophrenia, What do we really know?

2004 Invited Speaker, Strategic Research Institute conference on G-protein coupled receptor Drug Discovery World Summit

2003-2006 PhD thesis advisor to Nancy Rogacki (Hunter College, completed 2006)

2009Invited Speaker, CHDI (Huntington’s Disease) conference

2010Lecturer, Drew University, guest lectures in “Great Challenges in Neuroscience Research” classes

2011Invited Speaker, UMDNJ technology transfer seminar series

2011-2012 Advisory Board, Brain Health Institute, Rutgers University

2012Instructor, Biotechnology for non-scientists, ImClone Pharmaceuticals, sponsored by Raritan ValleyCommunity College, Branchburg, NJ

2012-2015 Expert Network, YourEncore Inc.

2012-2015 Council Member, Gerson Lehrman Group

2012-2015 Consultant, Guidepoint Global Advisor Network

2013 Speaker, CNS Drug Discovery and Development, a perspective from 20 years in Industry, College of Staten Island, New York

2013-2015 Guest Lecturer & Panel Discussion, Biochemical Pharmacology of receptors and ion channels, in Drug Discovery through Preclinical Development, Professional Master’s Program, Rutgers University

2013 Speaker, Univ Chicago Tech: CNS Drug Discovery and Development, Chicago, IL

2014 Speaker, Biotechnology Seminar Series: From Big Pharma to Startup Biotech, Columbia University

2014 Panelist, Careers in the Pharmaceutical Industry, Professional Master’s Program, Rutgers University

2014 Panelist, Alliance for Career Advancement, New Jersey Medical School, Rutgers University

2014 Industry Mentor, NSF iCorps Program, Rutgers Univ team

2014 Speaker, Innovation and Entrepreneurship: from Vertically Integrated to Distributed, Drew University RISE

2015 Guest speaker, Intrapreneurship, Commercializing Innovation course; Rutgers University

2015 Guest speaker, Entrepreneurship class, Singapore Management University

2015 Industry Mentor, UC BRAID iCorps Program, UCLA team

2015 Panelist, Google I/O Extended

2015-2016 Mentor, Rutgers Business School entrepreneurship course

2016 Speaker: CCIT (NJ Life Sciences Incubator): The importance of the Story in Team Building and Fundraising

2016 Speaker: Neuroconnections, Rutgers University: Travels of a Neuroscientist – from Academia to Big Pharma to Entrepreneurship and Consulting

2016 Speaker: iJOBs workshop: Drug Development in Biotechnology

2017 Speaker: ACA Rutgers University, Newark. Opportunities in Drug Discovery and Development

2017-19 Organizer: Regional Academic Drug Discovery Symposium, ILSE

2018, 2019 Lecturer: Fundraising; Drug Discovery & Development Course, NJ Medical School/Rutgers

2019 Workshops: Help us build a biotech company (iJOBS workshops, Rutgers & Princeton Univ)

Patents:

1.Kongsamut, S., C.P. Smith & A.T. Woods. U.S. Patent #5,356,910 October 18, 1994. Use of N-(Pyridinyl)-1H-indol-1-amines for the Treatment of Obsessive Compulsive Disorder.

2.Huger, F.P., S. Kongsamut, C.P. Smith & L. Tang. U.S. Patent #5,776,955 July 7, 1998. Use of unsubstituted and substituted N-(pyrrol-1-yl) pyridinamines as anticonvulsant agents.

3.Emmons, G., S. Kongsamut, C.N. Karson, C.M. Legoff. U.S. Patent #7,618,650 November 17, 2009. Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof.

4.Cao, B., V. Gurunian, S. Kongsamut, R.W. Kosley, Jr., R. Sher, R.E. Hartung. U.S. Patent #8,642,603 February 4, 2014. Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof.

5.Ioannou, Y.A., L. Altstiel, D.R.Crockford, S. Kongsamut U.S. Patent #9,724,328 August 8, 2017. Methods and compositions for treatment of lipid storage disorders.

Publications:

Original Research:

1.Shalaby, I.A., S. Kongsamut, S.B. Freedman & R.J. Miller. Life Sci. 35: 12891295, 1984. The Effects of Dihydropyridines on Neurotransmitter Release from Cultured Neuronal Cells.

2.Monsereenusorn, Y. & S. Kongsamut. Res. Commun. Chem. Pathol. Pharmacol. 47: 453456, 1985. Inhibition of Calcium Uptake by Capsaicin.

3.Kongsamut, S., S.B. Freedman & R.J. Miller. Biochem. Biophys. Res. Commun. 127: 7179, 1985. Dihydropyridine Sensitive Calcium Channels in a Smooth Muscle Cell Line.

4.Kongsamut, S., S.B. Freedman, B.E. Simon & R.J. Miller. Life Sci. 36: 14931501, 1985. Interactions of Steroidal Alkaloid Toxins with Calcium Channels in Neuronal Cell Lines.

5.Shangold, G.A., S. Kongsamut & R.J. Miller. Life Sci. 36: 22032215, 1985. Characterization of Voltage Sensitive Calcium Channels in a Clonal Pituitary Cell Line.

6.Kongsamut, S., T.J. Kamp, R.J. Miller & M.C. Sanguinettti. Biochem. Biophys. Res. Commun. 130: 141148, 1985. Calcium Channel Agonist and Antagonist Effects of the Stereoisomers of the Dihydropyridine 202791.

7.Harris, K.M., S. Kongsamut & R.J. Miller. Biochem. Biophys. Res. Commun. 134: 12981305, 1986. Protein Kinase C Mediated Regulation of Calcium Channels in PC12 Pheochromocytoma Cells.

8.Shalaby, I.A., S. Kongsamut & R.J. Miller. J. Neurochem. 46: 11611165, 1986. Maitotoxininduced Release of [3H]GABA from Cultures of Striatal Neurons.

9.Kongsamut, S. & R.J. Miller. Proc. Nat. Acad. Sci. (U.S.A.) 83: 22432247, 1986. Nerve Growth Factor Modulates the Drug Sensitivity of Neurotransmitter Release from PC12 Cells.

10.Kongsamut, S. & D.A. Nachshen. Biochim. Biophys. Acta 940: 241-246, 1988. Measurement of the Cytosolic Sodium Ion Concentration in Rat Brain Synaptosomes by a Fluorescence Method.

11.Nachshen, D.A. & S. Kongsamut. Biochim. Biophys. Acta 979: 305-310, 1989. 'Slow' K+stimulated Ca2+ influx is mediated by Na+/Ca2+ exchange: a pharmacological study.

12.Lipscombe, D., S. Kongsamut & R.W. Tsien. Nature 340: 639-642, 1989. a-Adrenergic inhibition of sympathetic neurotransmitter release mediated by modulation of N-type calcium channel gating.

13.Shibuya, I., S. Kongsamut & W.W. Douglas. Proc. Roy. Soc. Lond. Ser. B 243: 129-137, 1991. Studies on pituitary melanotrophs reveal the novel GABAB antagonist CGP 35348 to be the first such compound to be effective on endocrine cells.

14.Kongsamut, S., I. Shibuya, & W.W. Douglas. Neuroendocrinol. 54: 599-606, 1991. Why are Several Inhibitory Transmitters Present in the Innervation of Pituitary Melanotrophs? Actions and Interactions of Dopamine, GABA and Neuropeptide Y on Secretion from Neurointermediate Lobes of Xenopus laevis.

15.Shibuya, I., S. Kongsamut & W.W. Douglas. Brit. J. Pharmacol. 105: 893-898, 1992. Effectiveness of GABAB antagonists in inhibiting baclofen-induced reductions in cytosolic Ca2+ concentration in isolated melanotrophs of rat.

16.Kongsamut, S., I. Shibuya, M. Uehara & W.W. Douglas. Endocrinology 133: 336-342, 1993. Melanotrophs of Xenopus laevis respond directly to neuropeptide Y as evidenced by reductions in secretion and cytosolic Ca in isolated cells.

17.Smith, C.P., W. Petko, S. Kongsamut, J.E. Roehr, R.C. Effland, J.T. Klein and F.P. Huger. Drug Dev. Res. 32: 13-18, 1994. N(nPropyl)N(4Pyridinyl)1HIndol1amine (HP 749): mechanisms of in vitro [3H]norepinephrine release from rat cortical slices.

18.Smith, C.P., F.P. Huger, W. Petko & S. Kongsamut. Neurochem. Res. 19: 1265-1270, 1994. HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes.

19.Roehr, J.E., A.T. Woods R. Corbett & S. Kongsamut. Eur. J. Pharmacol. 278: 75-78, 1995. Changes in paroxetine binding in the cerebral cortex of polydipsic rats.

20.Tang, L., C.P. Smith, F.P. Huger & S. Kongsamut. Brit. J. Pharmacol. 116: 2468-2472, 1995. Effects of besipirdine at the voltage-dependent sodium channel.

21.Tang L. & S. Kongsamut. Eur. J. Pharmacol. 300: 71-74, 1996. Frequency dependent inhibition of neurotransmitter release by besipirdine.

22.Smith, C.P., A.T. Woods, R. Corbett, G. Bores, W. Petko, J.E. Roehr, S.M. Chesson F.P. Huger & S. Kongsamut. Neurochemical Res. 21: 575-583, 1996. Serotonergic activity of HP 184: does spontaneous release have a role?

23.Woods, A.T., C.P. Smith, R. Corbett, M.R. Szewczak, J.E. Roehr, G.M. Bores, J.T. Klein & S. Kongsamut. Brain Res. Bull. 41: 125-130, 1996. Besipirdine (HP 749) reduces scheduleinduced polydipsia in rats.

24.Hrib, N.J., J.G. Jurcak, D.E. Bregna, K.L. Burgher, H.B. Hartman, S. Kafka, L.L. Kerman, S. Kongsamut, J.E. Roehr, M.R. Szewczak, A.T. Woods-Kettelberger & R. Corbett. J. Med. Chem. 39: 4044-4057, 1996. Structure-Activity Relationships of a Series of Novel Piperazinyl Butyl Thiazolidinone Antipsychotic Agents Related to 3[4[4(6fluorobenzo[b]thien-3-yl0-1piperazinyl]butyl]-2,5,5trimethyl-4thiazolidinone maleate.

25.Kongsamut, S., J.E. Roehr, P. Weissensee, Hartman, H.B., J. Cai, L. Tang, L.L. Kerman & A. Sandrasagra. Eur. J. Pharmacol. 317: 417-423, 1996. Iloperidone binding to human dopamine and serotonin receptors.

26.Shibuya, I., S. Kongsamut & W.W. Douglas. Eur. J. Pharmacol. 321: 241-246, 1997. Both GABAA and GABAB receptors participate in suppression of [Ca2+]i pulsing in toad melanotrophs

27.Tang, L., F.P. Huger, J.T. Klein, L. Davis, S. Shimshock, L. Martin, R.C. Effland & S. Kongsamut. Drug Dev. Res. 44: 8-13, 1998. 4-Aminopyridine derivatives: a family of novel modulators of voltage-dependent sodium channels.

28.Kongsamut, S., J. Kang, X. Chen, J. Roehr & D. Rampe. Eur. J. Pharmacol. 450: 37-41, 2002. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.

29.Smith, C.P., S. Kongsamut, H. Wang, J. Ji, J. Kang & D. Rampe. Clin. Exp. Pharmacol. Physiol. 36: 1104-1109, 2009. In Vitro Electrophysiological Activity of Nerispirdine, a Novel 4-Aminopyridine Derivative.

30.Liang,G., X. Chen, S. Aldous, S-F Pu, S. Mehdi, E. Powers, A. Giovanni, S. Kongsamut, T. Xia, Y. Zhang, R. Wang, Z. Gao, G. Merriman, L.R. McLean & I. Morize. ACS Med. Chem. Lett. 3: 159-164, 2012. Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group.

31.Li, H., A. Eishingdrelo, S. Kongsamut & H. Eishingdrelo. Sig. Trans. Target. Ther. (Nature), 1: 16018, 2016. G protein-coupled receptors mediate 14-3-3 signal transduction. http://www.nature.com/articles/sigtrans201618

32.Griebel, G., P. Pichat, D. Boulay, V. Naimoli, L. Potestio, R. Featherstone, S. Sahni, H. Defex, C. Desvignes, F. Slowinski, X. Vigé, O.E. Bergis, R. Sher, R. Kosley, S. Kongsamut, M.D. Black, G.B. Varty. Nature Sci. Rep., 2016. The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. http://www.nature.com/articles/srep35320

33.Yuan, L., S. Barbash, S. Kongsamut, A. Eishingdrelo, T.P. Sakmar, H. Eishingdrelo. Sci. Rep. (Nature), 9: 11156, 2019. 14-3-3 signal adaptor and scaffold proteins mediate GPCR trafficking.

34.Eishingdrelo, H., X. Qin, L. Yuan, S. Kongsamut, L. Yu. Curr. Res. Pharmacol. Drug Discov. https://doi.org/10.1016/j.crphar.2022.100123. 2022. Ligands can differentially and temporally modulate GPCR interaction with 14-3-3 isoforms.

Reviews:

1.Monsereenusorn, Y., S. Kongsamut & P.D. Pezalla. CRC Crit. Rev. Toxicol. 10: 321339, 1982. Capsaicin A Literature Survey.

2.Fox, A.P., L.D. Hirning, S. Kongsamut, E.W. McCleskey, R.J. Miller, B.M. Olivera, T.M. Perney, S.A. Thayer & R.W. Tsien. in Neurotoxins and their Pharmacological Implications, Jenner, P. eds. Raven Press, NY, pp115131, 1987. The Interaction of Toxins with Calcium Channels.

3.Kongsamut, S. Proc. IBRO Workshop Bas. Neurosci. 1988. Cell Culture Methods - General Overview.

4.Kongsamut, S. Proc. IBRO Workshop Bas. Neurosci. 1988. Methods in Studying Neurotransmitter Release.

5.Kongsamut, S., Lipscombe, D. & R.W. Tsien. Ann. N.Y. Acad. Sci. 560: 312-333, 1989. The N-type Ca channel in frog sympathetic neurons and its role in the a-adrenergic modulation of transmitter release.

6.Lipscombe, D., S. Kongsamut & R.W. Tsien. Progress in Cell Research 1: 33-48, 1990. Ritchie J.M., Magistretti, P.J. & Bolis, L., eds. Elsevier Science Publishers. a-Adrenergic inhibition of N-type calcium channels and neurotransmitter release in sympathetic neurones.

7.Kongsamut, S. Thai J. Physiol. Sci. 3: 1-15, 1990. Invited Review: Pathways of calcium entry affecting neurotransmitter release.

8.Smith, C.P., A.T. Woods-Kettelberger, R. Corbett, R.D. Porsolt, J.E. Roehr, G. M. Bores, A. Giovanni, M.R. Szewczak, D.K. Rush, L.L. Martin, D.J. Turk, E.M. DiLeo, J.T. Klein, R.C. Effland, F.P. Huger & S. Kongsamut. CNS Drug Reviews 3: 1-23, 1997. Anti-obsessional and antidepressant profile of besipirdine.

9.Corbett, R., L. Griffiths, J.E. Shipley, U. Shukla, A.M. Szczepanik, M.R. Szewczak, D.J. Turk, H.M. Vargas, S. Kongsamut, and the Iloperidone Project Team. CNS Drug Reviews 3: 120-146, 1997. Iloperidone: Preclinical Profile and Early Clinical Evaluation.

10.Woods-Kettelberger, A.T., S. Kongsamut, C.P. Smith, J.T. Winslow & R. Corbett. Expert Opin. Invest. Drugs 6: 1369-1381, 1997. Animal Models with Potential Applications for Screening Compounds for the Treatment of Obsessive-Compulsive Disorder.

11.Eishingdrelo, H. and S. Kongsamut. Curr. Chem. Genom. Transl. Med. 7: 9-15, 2013. Minireview: Targeting GPCR Activated ERK Pathways for Drug Discovery.

12.Eishingdrelo, H., X. Qin, L. Yuan, S. Kongsamut, L. Yu. Curr. Res. Pharmacol. Drug Discov. https://doi.org/10.1016/j.crphar.2022.100123. 2022. Ligands can differentially and temporally modulate GPCR interaction with 14-3-3 isoforms.

13.Kongsamut, S. H. Eishingdrelo. Drug Discovery Today https://doi.org/10.1016/j.drudis.2023.103641. 2023.

Modulating GPCR and 14-3-3 protein interactions: Prospects for CNS drug discovery.

Contact this candidate